VRIGHT Exchange – Daily Sector-Wise Update | Thursday, September 11, 2025

Market Opening & Sentiment

• Pre-market cues: GIFT Nifty futures indicate a positive open around 25,084, supported by optimism around U.S.–India trade dialogue.

• Equities performance: Benchmarks extended their rally for a sixth straight day, with Nifty holding above 24,970 and Sensex consolidating near 81,425.

Macro & Global Insights
• Growth upgrade: Fitch revised India’s FY26 GDP forecast upward to 6.9% from 6.5%, citing robust Q2 growth and resilient services consumption. Another RBI rate cut is expected later this year.

• External sentiment: Trade optimism and easing tariff concerns continue to bolster foreign investor flows into Indian equities.

Sector Focus & Top Movers

IT & Tech
• Infosys-led momentum: IT sector is leading gains as Infosys stock rallies ahead of its board meeting on September 11 to consider a major share buyback.

Auto & Consumer
• Autos in demand: GST pass-through benefits and festive demand have pushed auto majors higher, with Maruti Suzuki hitting a fresh 52-week high.

Capex, Infra & Renewable

• Infrastructure tailwinds: Rail Vikas Nigam gained after being named lowest bidder on a ₹169 crore project. Tega Industries advanced on plans for a ₹1,500 crore acquisition.

Financials
• Banking spotlight: Kotak Mahindra Bank remained in focus amid speculation of a block deal involving Sumitomo Mitsui’s stake.

Market Risks & Headwinds

• Tariff uncertainties: While near-term trade tensions have eased, tariff risks remain a potential overhang for exporters.

• Monetary policy timing: Fed communication and RBI rate decisions in coming weeks may reset capital flow expectations.

What to Watch Next
• Infosys board meeting (Sept 11): Expected announcement on share buyback size and structure.

• U.S. Fed meeting (Sept 16–17): Critical for global risk flows and FPI sentiment.

• GST Council clarifications: Outcomes may influence consumer demand and sectoral pricing dynamics.

Corporate Updates

• Reliance Industries: Incorporated a new wholly-owned subsidiary, Reliance Intelligence.

• Rajoo Engineers: Signed a definitive agreement to acquire a manufacturing company producing machinery for multiple industries.

• Dr. Reddy’s Laboratories: Acquired Johnson & Johnson’s Stugeron portfolio for $50.5 million (₹445 crore), marking entry into the anti-vertigo therapy segment.

• Muthoot Capital: Successfully redeemed commercial paper worth ₹10 crore.

• Optiemus Infracom: Board approved a further investment of ₹7.69 crore in subsidiary Optiemus Electronics.

• Shipping Corporation of India: Took delivery of second-hand very large gas carrier “Shivalik” with 54,534 MT DWT capacity.

• Sasken Technologies: Chief Technology Officer, Girish BVS, resigned.

• Premier Explosives: Secured a ₹7.83 crore order from the Ministry of Defence for countermeasure supplies.

• Torrent Pharmaceuticals: To acquire 26% stake in Torrent Urja 27 for developing a captive hybrid solar-wind project in Gujarat.

• Bank of Baroda: Reduced MCLR by 10 bps to 7.85%, effective September 12.

• 63 Moons Technologies: Subsidiary 63sats Cybertech raised ₹180 crore via private placement.

• Keystone Realtors: Board approved fundraising of up to ₹375 crore through non-convertible debentures (face value ₹1 lakh each, private placement).

• Hindustan Foods: To propose merger of Avalon Cosmetics and Vanity Case India with itself.

• Highway Infrastructure:

o Won ₹69.77 crore NHAI contract for Muzaina Hetim toll plaza (U.P.).

o Secured ₹18.96 crore contract for user fee collection and facilities at Delhi–Vadodara Expressway toll plaza.

• Acme Solar Holdings: Clarified it has not received any update from the government on revocation of clean energy projects.

• Muthoot Finance: Infused fresh equity into subsidiary Muthoot Homefin via subscription to 2.6 crore shares.

• Tega Industries: Signed term sheet with Apollo Management Singapore and AIP MC Holdings to acquire 100% stake in Molycop for $1.48 billion EV through a consortium.

• Astral: Approved acquisition of the remaining 20% stake in subsidiary Astral Coatings for ₹75 crore.

• MedPlus Health: Subsidiary Optival Health received a 7-day drug license suspension from Drugs Control Administration; estimated potential revenue loss of ~₹1.21 lakh.

#VRIGHTExchange #MarketUpdates #CorporateNews #EconomyWatch #GlobalCues #DailyDigest #EquityInsights #InvestorUpdates #CorporateMoves #MarketPulse #SectorWatch
#InvestorEngagement #VRightExchange #Nifty #Nifty50 #BankNifty #StockMarket #StocksToWatch #StocksToTrade